Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
To the Editor.—In their thorough study, Dr Rosenberg and colleagues1 did not find that calcium antagonists increased the risk of malignancy, apart from renal cell carcinoma. By looking at all prospective randomized studies in which calcium antagonists were compared with another drug or with a placebo, we recently have confirmed their findings.2 However, the authors also reported an increased risk of renal cell carcinoma in patients taking a calcium antagonist and in those taking an angiotensin-converting enzyme inhibitor or a β-blocker and suggest, therefore, that hypertension, in and of itself, may be a risk for renal cell carcinoma.
Messerli FH, Grossman E. Antihypertensive Agents and the Risk of Cancer. JAMA. 1998;280(7):600. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-7-jbk0819-f